Synthesis and antibacterial activity of dihydro-1,2-oxazine and 2-pyrazoline oxazolidinones: Novel analogs of linezolid

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 11, 2005, Pages 2834-2839

  D'Andrea, Stan ^a   Zheng, Zhizhen Barbara ^a   DenBleyker, Kenneth ^a   Fung Tomc, Joan C ^a   Yang, Hyekyung ^a   Clark, Junius ^a   Taylor, Dennis ^a   Bronson, Joanne ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Antibacterial; Linezolid; Oxazolidinones

Indexed keywords

1,2 OXAZINE DERIVATIVE; ALKADIENE; EPEREZOLID; LINEZOLID; NITROSAMINE; OXAZOLIDINE DERIVATIVE; PYRAZOLINE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYCLOADDITION; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ACETAMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; GRAM-POSITIVE BACTERIA; MICE; MICROBIAL SENSITIVITY TESTS; OXAZOLES; OXAZOLIDINONES;

POSIBACTERIA;

EID: 19544392166     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.03.099     Document Type: Article

References (26)

1. M.R. Barbachyn, and C.W. Ford Angew. Chem., Int. Ed. 42 2003 2010 2023
2. Charles Stratton, MD. VRSA: The worst has finally happened. 42nd Intersci. Conf. Antimicrob Agents Chemother (ICAAC), San Diego, CA, September 27, 2002
3. AZD2563 is an oxazolidinone in early development at AstraZeneca. RBX-7644 (ranbezolid) is an oxazolidinone in early development at Ranbaxy. See: L.M. Ednie, A. Rattan, M.R. Jacobs, and P.C. Appelbaum Antimicrob. Agents Chemother. 47 2003 1143 1147
4. Ethan Rubinstein, MD. 43rd Intersci. Conf. Antimicrob Agents Chemother (ICAAC), September 14-17, 2003, Session 176(F,L) abstract#1782. (The need for an improved hematological profile is less clear cut for routine therapy: analysis of safety assessments on 2046 Zyvox patients and 2001 comparator drug-treated patients from seven Phase III clinical trials indicated virtually no differences in effects on hemoglobin, neutrophil, or platelet counts over the first 14 days of therapy. See: E. Rubinstein, R. Isturiz, H.C. Standiford, L.G. Smith, T.H. Oliphant, S. Cammarata, B. Hafkin, V. Le, and J. Remington Antimicrob. Agents Chemother. 47 2003 1824 1831)
5. Most of the oxazolidinones reported by Upjohn/Pharmacia to have superior safety profiles in a 30-day rat toxicity model have donating nitrogens in the para-position of the phenyl group. These agents include linezolid, eperezolid, U-100480 (thiomorpholine), and U-97456 (indoline). See Ref. 1. DuPont agents DuP-721 and DuP-105 lacking a para-amine functionality had more severe toxicity in a 30-day rat model (in house data)
6. M.A. Weidner-Wells, C.M. Boggs, B.D. Foleno, J. Melton, K. Bush, R.M. Goldschmidt, and D. Hlasta Bioorg. Med. Chem. Lett. 13 2003 4173 4177
7. H.Y. Kim, J.S. Lee, J.H. Cha, A.N. Pae, Y.S. Cho, M.H. Chang, and H.Y. Koh Bioorg. Med. Chem. Lett. 13 2003 2227 2230
8. Fukuda, Y.; Hammond, M. L. PCT. WO2003027083-A1, April 03, 2003
9. For a discussion of 3D-QSAR of 3-aryloxazolidinone antibacterials see: R.G. Karki, and V.M. Kulkarni Bioorg. Med. Chem. 9 2001 3153 3160
10. R.T. Coutts, and A. El-Hawari Heterocycles 2 1974 669 743
11. C.B. Ziegler Jr., P. Bitha, and Y. Lin J. Heterocycl. Chem. 25 1988 719
12. C.H. Park, D.R. Britelli, C.L.J. Wang, F.D. Marsh, W.A. Gregory, M.A. Wuonola, R.J. McRipley, V.S. Eberly, A.M. Slee, and M. Forbes J. Med. Chem. 35 1992 1156 1165
13. C.P. Chow, K.J. Shea, and S.M. Sparks Org. Lett. 4 2002 2637 2640
14. H. Labaziewicz, B.A. Howell, K.R. Lindfors, and R.C. Mason Heterocycles 34 1992 699 711
15. W.R. Perrault, B.A. Pearlman, D.B. Godrej, A. Jeganathan, K. Yamagata, J.J. Chen, C.V. Lu, P.M. Herrinton, R.C. Gadwood, L. Chan, M.A. Lyster, M.T. Maloney, J.A. Moeslein, M.L. Greene, and M.R. Barbachyn Org. Process Res. Dev. 7 2003 533 546
16. L. Urogdi, A. Patthy, E. Moravcsik, and L. Kisfaludy J. Heterocycl. Chem. 26 1989 129
17. F.G. Riddel, E.S. Turner, A.R. Katritzky, R.C. Patel, and F.M.S. Brito-Palma Tetrahedron 35 1979 1391
18. D.R. Williams, and M.H. Osterhout J. Am. Chem. Soc. 114 1992 8750 8751
19. Ihara Chem Ind Co Ltd; Japan Patent, JP-04244067, 92-337745, 1992
20. E.E. Boros, F. Bouvier, and M.H. Rabinowitz J. Heterocycl. Chem. 38 2001 613 616
21. 2). The MIC was defined as the lowest drug concentration that prevented physical growth
22. C.H. Park, D.R. Brittelli, C.L.J. Wang, F.D. Marsh, W.A. Gregory, M.A. Wuonola, R.J. McRipley, V.S. Eberly, A.M. Slee, and M. Forbes J. Med. Chem. 35 1992 1156 1165
23. The MIC of 25 against Streptococcus pneumoniae A9585 is actually quite impressive, but this determination was not repeated. Also, compound 25 had MIC's of 8 μg/mL against two other strains (S. pneumoniae A27881 and S. pneumoniae A28272) not included in Table 1
24. W.A. Gregory, and D.R. Brittelli J. Med. Chem. 33 1990 2569 2578
25. Staphylococcus aureus/Pen+ A15090, Inoculum 1.05 × 107 cfu/mouse ip in 7% mucin, drugs dissolved in 10% DMSO, 5% Tw-80, and water, administered orally b.i.d., 1 and 5 h post infection, death recorded for 8 days, 10 mice per group
26. 1H NMR and LC/MS)